PlainPharmaWatch

CMS Open Payments · Program Year 2024

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. reported $1,190,343.46 across General Payments, Research, and Ownership to 8,453 physicians and teaching hospitals across 8,463 transactions.

See the rankings → How this is sourced
$1.2M
All-tracks total
8,463
Transactions
8,453
Recipients
+$492.6K
General Payments vs PY2023

Catalyst Pharmaceuticals, Inc. reported $1,190,343.46 across all CMS Open Payments tracks (General + Research + Ownership) to 8,453 physicians and teaching hospitals in Program Year 2024 - ranking #582 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,065,562.46, averaging $140.82 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer catalyst-pharmaceuticals-inc Catalyst Pharmaceuticals, Inc.

$1.2M · #582/1,925 · 0.0% industry · PY2024

  • TOT $1.2M
  • RANK #582
  • SHARE 0.0%
  • TXN 8,463
  • RCP 8,453
  • CAT 6
  • GEN $1.1M
  • ΔGEN +$492.6K
  • TOP1 7.5%
  • PY 2024

Volume peers

Nearest volume peer: GenBioPro, Inc. ($1.2M)

The North Carolina Mutual Wh…$1.2MGenBioPro, Inc.$1.2MCatalyst Pharmaceuticals, In…$1.2MDiaSorin Inc.$1.2MBTG International, Inc.$1.2M
All-tracks payment totals near Catalyst Pharmaceuticals, Inc. (CMS Open Payments PY2024)

Catalyst Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Catalyst Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $492.6K (+86.0%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: CATALYST PHARMACEUTICALS, INC.PY2023: CATALYST PHARMACEUTICALS, INC.PY2024: CATALYST PHARMACEUTICALS, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$573.0KPY2024$1.1M
PY2023
$573,008.90
PY2024
$1,065,562.46

What the Data Shows for Catalyst Pharmaceuticals, Inc.

$1,190,343.46: that is what Catalyst Pharmaceuticals, Inc. reported in payments to 8,453 physicians and teaching hospitals during Program Year 2024, spread across 8,463 transactions ($140.65 per transaction, $140.82 per recipient). The company sits at rank #582 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

242 transactions worth $614.8K make "Honoraria" the top general-payment category in the 6-category breakdown below, 57.7% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Honoraria" leads Catalyst Pharmaceuticals, Inc.'s 6-category general-payment breakdown at $614.8K, 57.7% of the reported total.

Catalyst Pharmaceuticals, Inc. reports 6 general-payment categories - the top three are Honoraria (57.7%), Food and Beverage (18.2%), and Travel and Lodging (9.8%). The remaining 3 categories make up 14.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Catalyst Pharmaceuticals, Inc. divides its payments

Ranked by total dollars reported per category

1. Honoraria$614.8K2. Food and Beverage$194.1K3. Travel and Lodging$104.0K4. Consulting Fee$100.4K5. Grant$36.3K6. Education$16.1K
Payment Type Amount Transactions
Honoraria $614.8K 242
Food and Beverage $194.1K 6,865
Travel and Lodging $104.0K 325
Consulting Fee $100.4K 36
Grant $36.3K 11
Education $16.1K 974

Recipient Concentration in General Payments

The five largest recipient relationships account for $244,239.55 (22.9%) of $1,065,562.46 in this company's General Payments records across 2,946 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Catalyst Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Selim Ramin Benbadis$79.9KAtiya S. Khan$56.5KSteve S Chung$38.9KMatthew C. Holtzman$38.7KJesus Eric Pina Garza$30.2K
  1. 1

    Selim Ramin Benbadis

    $79,898.41 across 72 reported transactions

  2. 2

    Atiya S. Khan

    $56,525.79 across 62 reported transactions

  3. 3

    Steve S Chung

    $38,871.62 across 33 reported transactions

  4. 4

    Matthew C. Holtzman

    $38,710.28 across 47 reported transactions

  5. 5

    Jesus Eric Pina Garza

    $30,233.45 across 23 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Catalyst Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Catalyst Pharmaceuticals, Inc..

Gilead Sciences, Inc.

HHI 168

Dexcom, Inc.

HHI 168

Organogenesis Inc.

HHI 167

National Marrow Donor Program

HHI 169

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Catalyst Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Catalyst Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.